EGFR and non-small cell lung carcinoma: In fact, gefitinib and erlotinib – the first two oral EGFR TKIs to have reached the clinical arena – were initially investigated either alone or in combination with chemotherapy in unselected NSCLC populations based on the observation that the vast majority of lung tumour cells express EGFR on their surface [13].